This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Altimmune Class Action Lawsuit Filed
Regulatory class action

Altimmune Class Action Lawsuit Filed

Analysis based on 9 articles · First reported Aug 06, 2025 · Last updated Sep 07, 2025

Sentiment
-60
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is impacted by the significant decline in Altimmune's stock price following the disappointing trial results, leading to a federal securities class action lawsuit. This event highlights the risks associated with pharmaceutical development and can cause investors to re-evaluate their positions in similar biotechnology companies.

Biotechnology Legal Services
Event Summary

Altimmune, a publicly traded company, is facing a federal securities class action lawsuit initiated by Faruqi & Faruqi. This follows a dramatic 53.2% decline in Altimmune's stock price on June 26, 2025, after the company announced disappointing topline results from its IMPACT Phase 2b MASH trial of Pemvidutide. The trial failed to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint, which was attributed to a higher-than-expected placebo response. Faruqi & Faruqi, through partner James Wilson, is encouraging investors who suffered losses between August 10, 2023, and June 25, 2025, to contact them, with a deadline of October 6, 2025, to seek the role of lead plaintiff.

Entities Involved
stock
Altimmune
Altimmune is facing a federal securities class action lawsuit after its stock price declined dramatically following the announcement of disappointing Phase 2b MASH trial results for Pemvidutide.
Importance 100.0 Sentiment -80.0
priv
Faruqi & Faruqi
Faruqi & Faruqi, a national securities law firm, is investigating potential claims against Altimmune and encouraging investors to join a class action lawsuit.
Importance 70.0 Sentiment 20.0
per
James Wilson
James Wilson, a partner at Faruqi & Faruqi, is encouraging investors who suffered losses in Altimmune to contact him to discuss their legal options.
Importance 50.0 Sentiment 10.0
Relationships
Faruqi & Faruqi related ↔ James Wilson
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.